Preliminary DCR of 61% reported in evaluable Ph 2 advanced breast cancer patients treated with Bria-IMT
“We are extremely pleased to report clinical benefit with our regimen in a heavily pre-treated patient who had failed prior ADC treatment,” commented Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer. “In addition to the longer than expected progression free and overall survival, we note the absence of serious complications such as potentially fatal interstitial lung disease (ILD) commonly associated with follow-on ADC treatments. The data supports the Bria-IMT™ approach as a promising therapeutic alternative to chemotherapy in advanced metastatic breast cancer.”
Share:
More News
Søren Bregenholt, CEO of Alligator Bioscience, commented: “The orphan designation to HLX22 in Europe represents another important regulatory milestone for this program. Following the earlier FDA designation, this reinforces the potential clinical and commercial value of the antibody. While Alligator is not directly involved in the development, we look forward
Abbisko Therapeutics announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib, has received approval of Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for the treatment of Hepatocellular Carcinoma (HCC). Irpagratinib is the first therapeutic agent to leverage
Dr. Michael Ge, CEO of Kelun-Biotech said, “We are very pleased that the NDA application for the fourth indication of our core product, sac-TMT, has been accepted by the CDE of NMPA, which is another breakthrough for the breast cancer treatment field. This not only verifies the clinical value and
“The clearance of our IND for AVZO-1418 is a significant achievement for Avenzo as this is our second IND in 3 weeks to receive clearance and our first ADC program to advance into the clinic,” said Mohammad Hirmand, M.D., Co-founder and Chief Medical Officer of Avenzo Therapeutics. “We believe AVZO-1418
